Medicine and Dentistry
Adverse Event
6%
Androgen Deprivation Therapy
7%
Biochemical Recurrence
14%
Bladder
5%
Bladder Cancer
11%
Brachytherapy
7%
Cancer Cell
7%
Clear Cell Renal Cell Carcinoma
10%
Clinical Trial
5%
Computer Assisted Tomography
9%
Cone Beam Computed Tomography
5%
Contouring
7%
Disease
25%
Distant Metastasis
8%
DNA Repair
5%
Dosimetry
5%
Drug Megadose
7%
Enzalutamide
7%
Hazard Ratio
9%
Image-Guided Radiation Therapy
5%
Immunotherapy
8%
Intensity Modulated Radiation Therapy
15%
Lutetium 177
7%
Magnetic Resonance Imaging
19%
Malignant Neoplasm
10%
Metastatic Carcinoma
20%
Neoplasm
11%
Overall Survival
13%
Pelvis
6%
Placebo
7%
Progression Free Survival
9%
Prostate Cancer
100%
Prostate Specific Antigen
9%
Prostatectomy
16%
Quality of Life
5%
Radiation Oncology
6%
Radiation Therapy
95%
Radiology
11%
Radiotherapy Prostate Cancer
7%
Rectal Administration
5%
Recurrent Disease
14%
Somatics
5%
Stereotactic Body Radiation Therapy
19%
Systemic Therapy
10%
Treatment Planning
8%
Volumetric Modulated Arc Therapy
7%
Whole Body Radiation
7%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
6%
Androgen
7%
Biochemical Recurrence
9%
Bladder Cancer
11%
Carcinoma
6%
Cyclin D1
7%
Disease
18%
Distant Metastasis
7%
Enzalutamide
7%
Epidermal Growth Factor Receptor
6%
Erlotinib
7%
Malignant Neoplasm
20%
Metastasis
11%
Neoplasm
7%
Non Small Cell Lung Cancer
6%
Overall Survival
12%
Placebo
7%
Primary Tumor
6%
Progression Free Survival
7%
Prostate Cancer
65%
Prostate Specific Antigen
7%
Recurrent Disease
9%
Renal Cell Carcinoma
7%
Keyphrases
Clinical Experience
7%
Confidence Interval
5%
Localized Disease
5%
Localized Prostate Cancer
8%
NCCN Guidelines
8%
Prostate Cancer
31%
Prostate-specific Antigen
7%
Radiation Therapy
8%
Radical Prostatectomy
5%
Radiotherapy
5%
Recurrent Prostate Cancer
7%
Salvage Radiotherapy
11%
Stereotactic Ablative Radiotherapy
11%
Systemic Therapy
5%
Total Body Irradiation
7%
Volumetric Modulated Arc Therapy
7%